Please login to the form below
Norway
This page shows the latest Norway news and features for those working in and with pharma, biotech and healthcare.
BeiGene, Novartis' tislelizumab report promising topline results in nasopharyngeal cancer
As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront
Latest news
-
EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine
J&J is now set to resume its shipments of its vaccine to the EU, Norway and Iceland, adding in a statement that it has provided updated guidance for use of
-
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
As part of that agreement, Novartis gained development and commercialisation rights to tislelizumab in the US, Canada, Mexico, the EU, UK, Norway, Switzerland, Iceland, Liechtenstein, Russia and Japan for an upfront
-
Safety review shows ‘no evidence’ that AZ's vaccine causes increased risk of blood clots
jab. This includes Denmark, Norway, Iceland, the Netherlands, Bulgaria and Ireland, while additional countries have reportedly suspended the use of certain batches of AZ’s vaccine.
-
EMA says there is ‘no indication’ AZ/Oxford’s COVID-19 vaccine causes blood clots
This includes one case in Denmark, where a person died. In addition to Denmark, Norway and Iceland have also temporarily paused the rollout of the AZ/Oxford vaccine.
-
Gavi says 76 wealthy countries have committed to COVAX vaccine facility
According to Berkley, over 70 nations have now signed up to the facility, including Japan, Norway and Germany, to procure vaccines through the COVAX facility for their respective nations.
EMA finds overall benefit-risk ‘remains positive’ for J&J COVID-19 vaccine
BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC
Safety review shows ‘no evidence’ that AZ's vaccine causes increased risk of blood clots
EMA says there is ‘no indication’ AZ/Oxford’s COVID-19 vaccine causes blood clots
More from news
Approximately 1 fully matching, plus 132 partially matching documents found.
Latest Intelligence
-
Piloting a route to the biosimilars opportunities in Europe
Most biosimilar products are introduced into markets through tenders. We have seen discounts of 85% in Norway and 45% in France, following local negotiations.
-
Developing a COVID-19 vaccine
The Coalition for Epidemic Preparedness Innovations (CEPI), an Oslo, Norway-based nonprofit, is helping to coordinate the development of a COVID-19 vaccine and is leading the efforts to finance the
-
Will biosimilars ever catch on in the US?
Notably the biosimilar Renflexis (infliximab-abda) achieved a 70-80% price reduction to its reference product in both Norway and Denmark.
-
The case for a second Brexit referendum: “We need the informed consent of the people”
As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time.
-
The tipping point
National policy mandates to switch from the originator to biosimilars, as has been the case in Norway, have resulted in rapid and almost complete biosimilar market penetration.
Piloting a route to the biosimilars opportunities in Europe
Developing a COVID-19 vaccine
Will biosimilars ever catch on in the US?
The case for a second Brexit referendum: “We need the informed consent of the people”
The tipping point
More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.
Latest appointments
-
Gilead Sciences appoints general manager, Canada
Brysting was most recently general manager of Gilead Nordics, comprising the company's businesses in Sweden, Norway, Denmark, Finland and Iceland.
-
Targovax appoints chief financial officer
Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.
-
Algeta execs join Targovax
Anna-Kirsti Aksnes and Tina Madsen join the firm. Norway's Targovax has added to its senior team with the appointment of two executives from Algeta.
-
Anker Lundemose appointed CEO of Bionor Pharma
The Norway-based biotech, which is focused on peptide-based vaccines for HIV, said Dr Lundemose will take over the role from March 1, when his predecessor Steen Krøyer becomes deputy
-
Matt Regan named AbbVie’s general manager in UK
Was formerly general manager of Abbott in Norway. AbbVie, the new independent biopharma spin-out from Abbott, has appointed Matt Regan as general manager of its UK business. ... Regan was formerly general manager for Abbott in Norway and will now oversee
Gilead Sciences appoints general manager, Canada
Targovax appoints chief financial officer
Algeta execs join Targovax
Anker Lundemose appointed CEO of Bionor Pharma
Matt Regan named AbbVie’s general manager in UK
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
CEO Pricing & Market Access, UK
-
Six figure salary
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- David Hunt launches independent agency The Considered
- Embattled Biogen talks up Aduhelm
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Live Webinar: Unlocking the Potential of Electronic Medical Records Using Artificial Intelligence
- Queen's Award Highlights Video
- Innovative Trials wins the Queen’s Award
- Will most electronic consumer goods turn into medical devices after the MDR?
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- Biogen’s Vumerity recommended by CHMP in MS
- David Hunt launches independent agency The Considered
- WHO to test three more potential COVID-19 treatments
- Congress “concerned by apparent anomalies” around FDA’s approval of Aduhelm
- FDA clears BMS/AZ's dapagliflozin at second attempt
- Why you should feel optimistic about the future of healthcare
- Courageous Conversation ep.11: How to Inspire Creativity with Virtual Working Groups
PMHub
Visformatics (VISFO)
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....
Latest intelligence
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
- Rare thoughts & outcomes - navigating pathways to better outcomes in rare
- ...
